drugset / Trial / NCT07683832
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
Phase 0
Not yet recruiting
50 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Suzhou Abogen Biosciences Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of a personalized cancer vaccine alone and in combination with toripalimab in patients with resected NSCLC. The study included dose escalation and dose expansion two parts.
Timeline
- Start
- 2026-07-28
- Primary completion
- 2028-12-31
- Completion
- 2031-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABO2109 | Vaccine | — | Intramuscular |
| Subject | Toripalimab | Monoclonal antibody | — | — |